← Back to Screener
Anebulo Pharmaceuticals, Inc. Common Stock (ANEB)
Price$0.44
Favorite Metrics
Price vs S&P 500 (26W)-89.78%
Price vs S&P 500 (4W)-61.35%
Market Capitalization$17.94M
All Metrics
Book Value / Share (Quarterly)$0.19
P/TBV (Annual)5.42x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.14
Price vs S&P 500 (YTD)-60.57%
EPS (TTM)$-0.19
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.19
EPS (Annual)$-0.25
ROI (Annual)-72.78%
Cash / Share (Quarterly)$0.22
ROA (Last FY)-69.86%
EBITD / Share (TTM)$-0.20
ROE (5Y Avg)-117.03%
Cash Flow / Share (Annual)$-0.15
P/B Ratio2.26x
P/B Ratio (Quarterly)5.23x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-67.37x
ROA (TTM)-68.98%
EPS Incl Extra (Annual)$-0.25
Current Ratio (Annual)24.53x
Quick Ratio (Quarterly)6.12x
3-Month Avg Trading Volume0.08M
52-Week Price Return-57.69%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.33
52-Week High$3.42
EPS Excl Extra (Annual)$-0.25
26-Week Price Return-81.03%
Quick Ratio (Annual)23.99x
13-Week Price Return-60.36%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.24x
Enterprise Value$8.903
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.28
3-Month Return Std Dev183.34%
Net Income / Employee (TTM)$-4
ROE (Last FY)-72.78%
Net Interest Coverage (Annual)-31.20x
EPS Basic Excl Extra (Annual)$-0.25
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.19
ROI (TTM)-75.39%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.41
Price vs S&P 500 (52W)-92.79%
Year-to-Date Return-56.44%
5-Day Price Return-12.04%
EPS Normalized (Annual)$-0.25
ROA (5Y Avg)-111.06%
Month-to-Date Return-55.56%
Cash Flow / Share (TTM)$-0.36
EBITD / Share (Annual)$-0.25
ROI (5Y Avg)-117.03%
EPS Basic Excl Extra (TTM)$-0.19
P/TBV (Quarterly)6.89x
P/B Ratio (Annual)5.07x
Book Value / Share (Annual)$0.28
Price vs S&P 500 (13W)-63.23%
Beta-1.96x
Revenue / Share (TTM)$0.00
ROE (TTM)-75.39%
52-Week Low$0.30
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANEBAnebulo Pharmaceuticals, Inc. Common Stock | — | — | — | — | $0.44 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing treatments for cannabinoid toxicity and substance addiction, with operations focused in the United States. Its lead candidate, ANEB-001 (Selonabant), is designed to rapidly counteract acute cannabinoid intoxication and unintentional cannabis poisoning. The company targets an emerging therapeutic area with significant unmet medical needs.